Registry Study for Personalized Cancer Therapy

Objectives: Primary Objectives: To evaluate the anti-cancer activity of commercially available, targeted anti-cancer therapies used off-label for treatment in patients with advanced solid cancer with known genomic aberrations. Secondary Objectives: To determine outcomes of patients who were treated with matched targeted anti-cancer therapies based on known genomic aberrations. To obtain treatment related adverse events in patients with advanced solid tumor who were treated with off -label targeted therapies. To determine co-genomic aberrations that may contribute to treatment response or resistance mechanisms. To determine feasibility of detecting the genomic alterations in plasma, and the genomic evolution of circulating biomarkers.